Qlife Holding ABFRA:4HG0 -1.41%25 EBITDA Margin % is -25,550.00% as of Mar. 2026. GuruFocus rates FRA:4HG0 with a GF Score™ of 25/100 and a GF Value™ of €0.06 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Qlife Holding AB ranks worse than 97.92% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Qlife Holding AB's EBITDA for the
three
months ended in Mar. 2026 was €-0.51 Mil. Qlife Holding AB's Revenue for the
three
months ended in Mar. 2026 was €0.00 Mil. Therefore, Qlife Holding AB's EBITDA margin for the quarter that ended in Mar. 2026 was -25,550.00%.
Qlife Holding AB (FRA:4HG0) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Qlife Holding AB EBITDA Margin % Related Terms
Qlife Holding AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Qlife Holding AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4HG0 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Qlife Holding AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qlife Holding AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Qlife Holding AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Qlife Holding AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qlife Holding AB (FRA:4HG0) has a EBITDA Margin % of -25,550.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Qlife Holding AB and its competitors. According to the industry distribution chart, Qlife Holding AB ranks #799 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 97.9%.
Is Qlife Holding AB's EBITDA Margin % too high?
Qlife Holding AB's current EBITDA Margin % is -25,550.00%. Based on the distribution chart, Qlife Holding AB ranks #799 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Qlife Holding AB has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qlife Holding AB's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Qlife Holding AB ranks #799 out of 816 companies for EBITDA Margin %. This places Qlife Holding AB in the lower half of its industry. The industry median EBITDA Margin % is 7.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.46, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Qlife Holding AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qlife Holding AB's current EBITDA Margin % is -25,550.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qlife Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Qlife Holding AB (FRA:4HG0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.06, compared to a current price of €0.15 — trading 156.7% above its estimated fair value. The current EBITDA Margin % is -25,550.00%. Qlife Holding AB's overall GF Score™ is 25/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Qlife Holding AB (FRA:4HG0), the current EBITDA Margin % is -25,550.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qlife Holding AB (FRA:4HG0) Overvalued in 2026?
Based on GuruFocus' analysis, Qlife Holding AB stock appears to be overvalued.
The current stock price of €0.15 is trading 156.7% above its estimated GF Value™ of €0.06.
GuruFocus considers Qlife Holding AB to be Significantly Overvalued.
Key valuation signals for FRA:4HG0:
EBITDA Margin %: -25,550.00%
GF Value™: €0.06 vs. price of €0.15 (156.7% above fair value)
No single metric tells the full story. See the FRA:4HG0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qlife Holding AB is a medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it. The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient's doctor, clinic or hospital via smartphone and computer.
25GF Score
Get the complete analysis for FRA:4HG0
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4HG0 has been successfully added to your 
